Clonoseq
Payments companies reported to CMS as associated with Clonoseq. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Clonoseq, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Clonoseq
These are the largest totals companies reported as associated with Clonoseq. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Gaurav Singal | Boston, MA | Internal Medicine | $157,584.00 |
| Stephan Grupp | Philadelphia, PA | Pediatric Hematology-Oncology | $84,860.69 |
| Nicholas Short | Houston, TX | Internal Medicine | $81,301.44 |
| Georges Azzi | Fort Lauderdale, FL | Hematology & Oncology | $41,303.80 |
| Ryan Jacobs | Charlotte, NC | Hematology (Internal Medicine) | $32,480.25 |
| Rushang Patel | Orlando, FL | Medical Oncology | $32,261.39 |
| Anthony Mato | Ithaca, NY | Medical Oncology | $31,509.99 |
| Joshua Richter | New York, NY | Medical Oncology | $24,624.75 |
| Moshe Levy | Dallas, TX | Medical Oncology | $22,814.24 |
| Edward Pearson | Dallas, TX | Hematology & Oncology | $21,997.08 |
Prescribed Clonoseq?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.